Literature DB >> 26308881

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

Mallory R Gordon1, Mine Canakci1, Longyu Li1, Jiaming Zhuang1, Barbara Osborne1, S Thayumanavan1.   

Abstract

Antibody-drug conjugates have attracted a great amount of attention as a therapeutic strategy for diseases where targeting specific tissues and cells are critical components, such as in cancer therapy. Although promising, the number of approved ADC drugs is relatively limited. This emanates from the challenges associated with generating the conjugates and the complexities associated with the stability requirements for these conjugates during circulation and after reaching the target. Here, we provide a comprehensive overview of the design challenges facing the ADC field. These challenges also provide several unique research and development opportunities, which are also highlighted throughout the review.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26308881      PMCID: PMC4933296          DOI: 10.1021/acs.bioconjchem.5b00399

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  112 in total

Review 1.  Glutathione metabolism and its implications for health.

Authors:  Guoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R Lupton; Nancy D Turner
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

2.  N-terminal labeling of proteins by the Pictet-Spengler reaction.

Authors:  Tsubasa Sasaki; Koichiro Kodama; Hiroaki Suzuki; Seketsu Fukuzawa; Kazuo Tachibana
Journal:  Bioorg Med Chem Lett       Date:  2008-07-15       Impact factor: 2.823

3.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

4.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

Review 5.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

6.  The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.

Authors:  B H Petersen; S V DeHerdt; D W Schneck; T F Bumol
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

7.  Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting.

Authors:  Marina Talelli; Cristianne J F Rijcken; Sabrina Oliveira; Roy van der Meel; Paul M P van Bergen En Henegouwen; Twan Lammers; Cornelus F van Nostrum; Gert Storm; Wim E Hennink
Journal:  J Control Release       Date:  2011-01-22       Impact factor: 9.776

8.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

9.  Double click: dual functionalized polymeric micelles with antibodies and peptides.

Authors:  Dianna P Y Chan; Shawn C Owen; Molly S Shoichet
Journal:  Bioconjug Chem       Date:  2013-01-04       Impact factor: 4.774

10.  Protein modification, bioconjugation, and disulfide bridging using bromomaleimides.

Authors:  Mark E B Smith; Felix F Schumacher; Chris P Ryan; Lauren M Tedaldi; Danai Papaioannou; Gabriel Waksman; Stephen Caddick; James R Baker
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

View more
  17 in total

1.  Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.

Authors:  Thomas Botzanowski; Stéphane Erb; Oscar Hernandez-Alba; Anthony Ehkirch; Olivier Colas; Elsa Wagner-Rousset; David Rabuka; Alain Beck; Penelope M Drake; Sarah Cianférani
Journal:  MAbs       Date:  2017-04-13       Impact factor: 5.857

2.  Targeting CD4+ Cells with Anti-CD4 Conjugated Mertansine-Loaded Nanogels.

Authors:  Mine Canakci; Khushboo Singh; Oyuntuya Munkhbat; Sudarvili Shanthalingam; Ankita Mitra; Mallory Gordon; Barbara A Osborne; S Thayumanavan
Journal:  Biomacromolecules       Date:  2020-05-28       Impact factor: 6.988

3.  Stable and Potent Selenomab-Drug Conjugates.

Authors:  Xiuling Li; Christopher G Nelson; Rajesh R Nair; Lori Hazlehurst; Tina Moroni; Pablo Martinez-Acedo; Alex R Nanna; David Hymel; Terrence R Burke; Christoph Rader
Journal:  Cell Chem Biol       Date:  2017-03-16       Impact factor: 8.116

Review 4.  Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.

Authors:  Xingshu Li; Jihoon Kim; Juyoung Yoon; Xiaoyuan Chen
Journal:  Adv Mater       Date:  2017-03-29       Impact factor: 30.849

5.  Rapid formation of a stable boron-nitrogen heterocycle in dilute, neutral aqueous solution for bioorthogonal coupling reactions.

Authors:  Ozlem Dilek; Zhen Lei; Kamalika Mukherjee; Susan Bane
Journal:  Chem Commun (Camb)       Date:  2015-12-11       Impact factor: 6.222

6.  Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency.

Authors:  Long Chen; Justin Cohen; Xiaoda Song; Aishan Zhao; Zi Ye; Christine J Feulner; Patrick Doonan; Will Somers; Laura Lin; Peng R Chen
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

7.  Development of a facile antibody-drug conjugate platform for increased stability and homogeneity.

Authors:  Nimish Gupta; Johny Kancharla; Shelly Kaushik; Aasif Ansari; Samad Hossain; Ravinder Goyal; Manoj Pandey; Jwala Sivaccumar; Sazid Hussain; Arindam Sarkar; Aniruddha Sengupta; Swadhin K Mandal; Monideepa Roy; Shiladitya Sengupta
Journal:  Chem Sci       Date:  2016-12-09       Impact factor: 9.825

8.  Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.

Authors:  Allison R Sirois; Daniela A Deny; Samantha R Baierl; Katia S George; Sarah J Moore
Journal:  PLoS One       Date:  2018-05-08       Impact factor: 3.240

9.  Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.

Authors:  Yasuaki Anami; Chisato M Yamazaki; Wei Xiong; Xun Gui; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Nat Commun       Date:  2018-06-28       Impact factor: 14.919

10.  Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation.

Authors:  Elena Cini; Valentina Faltoni; Elena Petricci; Maurizio Taddei; Laura Salvini; Giuseppe Giannini; Loredana Vesci; Ferdinando Maria Milazzo; Anna Maria Anastasi; Gianfranco Battistuzzi; Rita De Santis
Journal:  Chem Sci       Date:  2018-07-03       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.